Researchers from the Memorial Sloan Kettering Cancer Center have reported a median event-free survival (EFS) of 6.1 months at a median follow-up of 29 months among patients with relapsed B-ALL who received CD19 CAR-T infusion. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.